<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812015</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00107689</org_study_id>
    <nct_id>NCT04812015</nct_id>
  </id_info>
  <brief_title>Learning and Ear Stimulation</brief_title>
  <official_title>Optimizing Transdiagnostic Non-invasive Vagus Nerve Stimulation to Enhance Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine how non-invasive ear stimulation affects learning. During this&#xD;
      study, participants will be asked to complete surveys and come to a lab for about 2.5 hours.&#xD;
      Researchers will measure brain waves and other body responses (heart rate), while while the&#xD;
      ear is stimulated. Participants also will be asked to complete computer tasks. Because brain&#xD;
      activity will be measured, participants will be asked to come to the study with clean, dry&#xD;
      hair. The study is at MUSC in Charleston. Participants will be compensated for their time. To&#xD;
      be eligible, participants must be 18-65 years old, be able to commit 2.5 hours of time to the&#xD;
      study, and be able to wear sensors on their hands, arms, and head and sit quietly at a&#xD;
      computer.&#xD;
&#xD;
      There are some risks to completing this study. Some questions in the surveys ask about&#xD;
      personal thoughts and feelings. The ear stimulation may cause tingling sensations or&#xD;
      irritation around the ear.&#xD;
&#xD;
      There are no direct benefits to participants. This study will help researchers improve this&#xD;
      ear stimulation as a treatment method.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>Baseline to Active Stimulation (10-80 minutes apart) and Baseline to Recovery (90 minutes apart)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Skin Conductance Levels</measure>
    <time_frame>Baseline to Active Stimulation (10-80 minutes apart) and Baseline to Recovery (90 minutes apart)</time_frame>
    <description>Galvanic Skin Response measured in micro Siemens (mS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in P300 Amplitude</measure>
    <time_frame>Measured at 20-30, 50-60, and 80-90 minutes during stimulation</time_frame>
    <description>Measured for standard versus deviant tones during the Auditory Oddball Task. Oddball will be administered at 3 intervals during stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupillometry (Pupil Response)</measure>
    <time_frame>Baseline to Active Stimulation (10-80 minutes apart) and Baseline to Recovery (90 minutes apart)</time_frame>
    <description>Tonic Pupil Size and Event-Related Pupil Dilation measured in millimeters (mm)</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Learning</condition>
  <condition>taVNS</condition>
  <arm_group>
    <arm_group_label>Dose Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcutaneous auricular vagus nerve stimulation (taVNS) 10 minutes</intervention_name>
    <description>Sham 80 minutes and taVNS active stimulation for 10 minutes</description>
    <arm_group_label>Dose Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 20 minutes</intervention_name>
    <description>Sham 70 minutes and taVNS active stimulation for 20 minutes</description>
    <arm_group_label>Dose Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 30 minutes</intervention_name>
    <description>Sham 60 minutes and taVNS active stimulation for 30 minutes</description>
    <arm_group_label>Dose Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 40 minutes</intervention_name>
    <description>Sham 50 minutes and taVNS active stimulation for 40 minutes</description>
    <arm_group_label>Dose Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 50 minutes</intervention_name>
    <description>Sham 40 minutes and taVNS active stimulation for 50 minutes</description>
    <arm_group_label>Dose Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 60 minutes</intervention_name>
    <description>Sham 30 minutes and taVNS active stimulation for 60 minutes</description>
    <arm_group_label>Dose Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 70 minutes</intervention_name>
    <description>Sham 20 minutes and taVNS active stimulation for 70 minutes</description>
    <arm_group_label>Dose Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 80 minutes</intervention_name>
    <description>Sham 10 minutes and taVNS active stimulation for 80 minutes</description>
    <arm_group_label>Dose Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS 90 minutes</intervention_name>
    <description>Sham 0 minutes and taVNS active stimulation for 90 minutes</description>
    <arm_group_label>Dose Group 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Non-treatment-seeking community members who do not have a mental health diagnosis and&#xD;
             individuals seeking treatment for an anxiety, mood, trauma-related, or&#xD;
             obsessive-compulsive disorder.&#xD;
&#xD;
          -  Treatment and non-treatment-seeking community members with anxiety, mood,&#xD;
             trauma-related, or obsessive-compulsive disorder or symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of COVID-19 in the past 14 days&#xD;
&#xD;
          -  Facial or ear pain or recent ear trauma&#xD;
&#xD;
          -  Metal implant devices in the head, heart or neck&#xD;
&#xD;
          -  History of brain stimulation or other brain surgery&#xD;
&#xD;
          -  History of myocardial infarction or arrhythmia, bradycardia&#xD;
&#xD;
          -  Use of B-blockers, antiarrhythmic medication (sodium/potassium/calcium-channel&#xD;
             blockers), or blood pressure medications.&#xD;
&#xD;
          -  Active respiratory disorder&#xD;
&#xD;
          -  Personal or family history of seizure or epilepsy or personal use of medications that&#xD;
             substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium).&#xD;
&#xD;
          -  Personal history of head injury, concussion, or self-report of moderate to severe&#xD;
             traumatic brain injury&#xD;
&#xD;
          -  Individuals suffering from frequent/severe headaches&#xD;
&#xD;
          -  Individuals with lifetime evidence of severe psychiatric disorder (e.g.,&#xD;
             schizophrenia) or neurological disorder.&#xD;
&#xD;
          -  Moderate to severe alcohol or substance use disorder.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danielle L Taylor, PhD</last_name>
    <phone>8437904868</phone>
    <email>taydanie@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Danielle L Taylor, PhD</last_name>
      <phone>843-790-4868</phone>
      <email>taydanie@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Danielle Taylor, PhD</investigator_full_name>
    <investigator_title>Postdoctoral Research Fellow</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

